Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 6INDUSTRY 4NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm Metastasis 2Ovarian Neoplasms 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 41Cisplatin 38Paclitaxel 34Specimen Handling 32Radiotherapy 27Magnetic Resonance Spectroscopy 25Gemcitabine 23Vinorelbine 15Etoposide 15Docetaxel 15Biopsy 13Pemetrexed 10Cyclophosphamide 10pembrolizumab 9Taxes 9Immunoglobulin G 9Disulfides 9Platinum 81,2-diaminocyclohexaneplatinum II citrate 8X-Rays 7Vinblastine 7Erlotinib Hydrochloride 7osimertinib 6durvalumab 6atezolizumab 6Nivolumab 6Irinotecan 6Ifosfamide 6Chemotherapy, Adjuvant 6Celecoxib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lung Neoplasms × sotorasib × Clear all
NCT07012031 2026-05-13

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

National Cancer Institute (NCI)

Phase 1/2 Recruiting
37 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡